Eliem Therapeutics (ELYM) Stock Forecast, Price Target & Predictions
ELYM Stock Forecast
Eliem Therapeutics stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ELYM Analyst Ratings
According to 2 Wall Street analysts, Eliem Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ELYM stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 16, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Jul 11, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Apr 26, 2022 | Guggenheim | - | Neutral | Downgrade |
Eliem Therapeutics's last stock rating was published by SVB Leerink on Aug 16, 2022. The company gave ELYM a "Outperform" rating, the same as its previous rate.
Eliem Therapeutics Financial Forecast
Eliem Therapeutics Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - |
| High Forecast | - | - | - | - | - |
| Low Forecast | - | - | - | - | - |
| # Analysts | - | - | - | - | 1 |
| Surprise % | - | - | - | - | - |
Eliem Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. ELYM's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Eliem Therapeutics EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| EBITDA | - | - | - | $-5.12M | $-5.00M |
| Avg Forecast | - | - | - | - | - |
| High Forecast | - | - | - | - | - |
| Low Forecast | - | - | - | - | - |
| Surprise % | - | - | - | - | - |
undefined analysts predict ELYM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Eliem Therapeutics's previous annual EBITDA (undefined) of $NaN.
Eliem Therapeutics Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| Net Income | - | - | - | $-3.64M | $-3.97M |
| Avg Forecast | $46.78M | $40.75M | $43.57M | $-3.60M | $-3.79M |
| High Forecast | $46.78M | $40.75M | $43.57M | $-3.60M | $-3.79M |
| Low Forecast | $46.78M | $40.75M | $43.57M | $-3.60M | $-3.79M |
| Surprise % | - | - | - | 1.01% | 1.05% |
Eliem Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ELYM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Eliem Therapeutics SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| SG&A | - | - | - | $2.00M | $2.13M |
| Avg Forecast | - | - | - | - | - |
| High Forecast | - | - | - | - | - |
| Low Forecast | - | - | - | - | - |
| Surprise % | - | - | - | - | - |
Eliem Therapeutics's average Quarter SG&A projection for Mar 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to ELYM last annual SG&A of $2.00M (Dec 23).
Eliem Therapeutics EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| # Analysts | - | - | - | - | 1 |
| EPS | - | - | - | $-0.13 | $-0.15 |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $-0.13 | $-0.14 |
| High Forecast | $1.54 | $1.34 | $1.58 | $-0.13 | $-0.14 |
| Low Forecast | $1.54 | $1.34 | $1.58 | $-0.13 | $-0.14 |
| Surprise % | - | - | - | 1.00% | 1.07% |
According to undefined Wall Street analysts, Eliem Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ELYM previous annual EPS of $NaN (undefined).
Eliem Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| IPSC | Century Therapeutics | $1.60 | $20.00 | 1150.00% | Buy |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| AVTE | Aerovate Therapeutics | $1.90 | $13.00 | 584.21% | Hold |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| STTK | Shattuck Labs | $3.81 | $12.00 | 214.96% | Buy |
| PEPG | PepGen | $9.48 | $29.50 | 211.18% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| RZLT | Rezolute | $5.25 | $13.00 | 147.62% | Buy |
| ACRV | Acrivon Therapeutics | $8.91 | $21.50 | 141.30% | Buy |
| PHVS | Pharvaris | $20.92 | $38.50 | 84.03% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| ADAG | Adagene | $3.49 | $5.00 | 43.27% | Buy |
| CYT | Cyteir Therapeutics | $3.02 | $2.00 | -33.77% | Sell |
ELYM Forecast FAQ
Is Eliem Therapeutics a good buy?
Yes, according to 2 Wall Street analysts, Eliem Therapeutics (ELYM) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of ELYM's total ratings.
What are Eliem Therapeutics's analysts' financial forecasts?
ELYM's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-7.391M (high $-7.391M, low $-7.391M), average SG&A $0 (high $0, low $0), and average EPS is $-0.27 (high $-0.27, low $-0.27).